Allegan-based Perrigo Co. (Nasdaq: PRGO) Wednesday announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), previously Barr Laboratories Inc., has begun shipping Triamcinolone Acetonide Nasal Spray.
Perrigo’s partner Teva was the first applicant to file a complete Abbreviated New Drug Application with the United States Food and Drug Administration for Nasacort AQ and will be launching the product with 180 days of generic exclusivity.
The Hatch Waxman litigation between Teva and Sanofi was settled in 2008. The product was developed and will be manufactured at Perrigo. Perrigo will share in the costs and benefits in Teva’s marketing of the products under the agreement.
The product is the AB-rated equivalent to Sanofi’s Nasacort AQ, indicated for the treatment of the nasal symptoms of seasonal and year round allergies in adults and children six years of age and older. Sales for the brand were approximately $226 million, according to Wolters Kluwer data for the twelve months ending May 2011.
Said Perrigo chairman and CEO Joseph C. Papa: “The launch of triamcinolone nasal spray is a terrific example of Perrigo’s strategic focus on developing challenging products in the extended topical categories. It further demonstrates our strategy to deliver quality affordable healthcare for generic prescriptions and over the counter products.”
Perrigo develops, manufactures and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company is the world’s largest store brand manufacturer of OTC pharmaceutical products and infant formulas. Perrigo’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia.
More at www.perrigo.com.